Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 28, 2019 - Issue 10
Submit an article Journal homepage
365
Views
15
CrossRef citations to date
0
Altmetric
Review

Investigational MET inhibitors to treat Renal cell carcinoma

Lakshminarayanan NandagopalDepartment of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1610-8783View further author information
ORCID Icon,
Guru P. SonpavdeDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USAView further author information
&
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USAView further author information
Pages 851-860 | Received 01 Apr 2019, Accepted 24 Sep 2019, Published online: 03 Oct 2019

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Giacomo Nuvola, Alessandro Rizzo, Matteo Santoni, Veronica Mollica & Francesco Massari. (2022) Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development 7:1, pages 131-149.
Read now

Articles from other publishers (14)

James Nicholas Brundage, Kamal Kant Sahu & Benjamin Louis Maughan. (2023) MET Inhibitors for Papillary Renal Cell Carcinoma. Kidney Cancer 7:1, pages 67-80.
Crossref
Chiyu Zhang, Gaomin Huang, Jiale Yang, Yi Jiang, Ruizhen Huang, Zhenfeng Ye, Yawei Huang, Honglin Hu & Xiaoqing Xi. (2023) Overexpression of DBT suppresses the aggressiveness of renal clear cell carcinoma and correlates with immune infiltration. Frontiers in Immunology 14.
Crossref
Colya N. Englisch, Friedrich Paulsen & Thomas Tschernig. (2022) TRPC Channels in the Physiology and Pathophysiology of the Renal Tubular System: What Do We Know?. International Journal of Molecular Sciences 24:1, pages 181.
Crossref
Yohei Sekino, Jun Teishima, Gangning Liang & Nobuyuki Hinata. (2022) Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. International Journal of Urology 29:12, pages 1419-1428.
Crossref
Stefano Fogli, Fabrizio Tabbò, Annalisa Capuano, Marzia Del Re, Francesco Passiglia, Federico Cucchiara, Cristina Scavone, Veronica Gori, Silvia Novello, Manuela Schmidinger & Romano Danesi. (2022) The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. Critical Reviews in Oncology/Hematology 172, pages 103602.
Crossref
Ke Cheng, Xiao-Yu Li, Yu-Wen Zhou, Zheng-Yin Liao, Meng Qiu, Feng Bi & Li Zheng. (2021) Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial. The Oncologist 26:8, pages 649-e1313.
Crossref
Tien-Dzung Tran & Duc-Tinh Pham. (2021) Identification of anticancer drug target genes using an outside competitive dynamics model on cancer signaling networks. Scientific Reports 11:1.
Crossref
Chao Wu, Zuowei Wu & Bole Tian. (2020) Five gene signatures were identified in the prediction of overall survival in resectable pancreatic cancer. BMC Surgery 20:1.
Crossref
Venkata Ramesh Dasari, David J. Carey & Radhika Gogoi. (2020) Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells. BMC Cancer 20:1.
Crossref
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu & Yingbin Liu. (2020) Overview of current targeted therapy in gallbladder cancer. Signal Transduction and Targeted Therapy 5:1.
Crossref
Zhongyi Mu, Dan Dong, Mingli Sun, Liwen Li, Ning Wei & Bin Hu. (2020) Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology 10.
Crossref
Manuel Caitano Maia, Meghan Salgia & Sumanta K. Pal. (2020) Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nature Reviews Urology 17:5, pages 271-291.
Crossref
Shoichiro Mukai, Koji Yamasaki, Masato Fujii, Takahiro Nagai, Naoki Terada, Hiroaki Kataoka & Toshiyuki Kamoto. (2020) Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers. International Journal of Molecular Sciences 21:8, pages 2663.
Crossref
Yuan-Hong Xie, Ying-Xuan Chen & Jing-Yuan Fang. (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy 5:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.